Ask AI
Pharmacist Excellence in RRMM

CE

Advancing Pharmacist Excellence in RRMM: Optimizing Bispecific Antibody Selection, Safety, and Patient Care

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: June 29, 2026

Expiration: December 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with RRMM do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

An important part of therapy is counseling a patient on expectations when they receive treatment with a bispecific antibody for R/R multiple myeloma.

During the pharmacy education visit, patient BH expresses concern about the risk of infection with linvoseltamab. What prophylaxis measures should be discussed with patient BH?

4.

Based on clinical trial data and real-world evidence, there are some key differences when comparing the drug linvoseltamab to other bispecific antibodies.

A major difference of linvoseltamab includes the following:

5.

Which of the following toxicities is  characteristic of GPRC5D-targeted agents compared to  BCMA-targeted bispecific therapies?

6.

BH started initial treatment with linvoseltamab and began experiencing a fever of 101.4°F and generalized muscle aches. BH went to the Emergency Department, and they called you for guidance on the most appropriate management.

What would you recommend as the appropriate guideline-based management for the cytokine release syndrome that BH is experiencing?